Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2014 / Sayı: 1

Beyine İlaç Tașınması: Truva Atı Teknolojisi

Pages
1–16
Publication Date
2014-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, the aim of this present review is to evaluate the targeting approaches of colloidal systems and current studies for the development of new strategies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Delivery Systems for Brain Drug Targeting, Ankara, 2013.
📊
Key Findings & Data:The only way to overcome this treatment-limiting obstacle could be reached by the help of new strategies.
💡
Conclusion & Impact:Therefore, the aim of this present review is to evaluate the targeting approaches of colloidal systems and current studies for the development of new strategies.
🔬Design:Review & Systematic Survey
📍Scope:2013 Verileri
⚙️Variables:İlaç hedeflendirme · kan-beyin engeli · nanopartiküler sistemler

Abstract

Delivery Systems for Brain Drug Targeting, Ankara, 2013. Blood-brain barrier is the main factor which maintains homeostasis by protecting brain from toxic and harmful compounds, but it also represents the main limiting factor for a number of drug molecules to reach the aimed areas in brain. The only way to overcome this treatment-limiting obstacle could be reached by the help of new strategies. Nanoscale colloidal systems are promising strategies in the treatment of central nervous system CNS diseases by passive and active targeting. Receptor mediated transport systems RMT are in the spotlıght of targeting strategies.By the help of Molecular Trojan Technology, which is developed for receptor targeting, large molecule drugs will be transported to brain. Nowadays, research interest in targeted delivery systems in the treatment of CNS disorders has been focused on brain cancer, stroke, Alzheimer’s disease, Parkinson disease. Therefore, the aim of this present review is to evaluate the targeting approaches of colloidal systems and current studies for the development of new strategies.

Özet

Beyine İlaç Taşınmasında Kullanılan Taşıyıcı Sistemler, Ankara, 2013. KBE, beyni toksik ve zararlı bileşiklerden koruyarak homeostazı sağlayan, aynı zamanda pek çok etkin maddenin beyindeki hedef bölgelere ulaşmasını kısıtlayan en önemli faktördür. Tedaviyi sınırlayan bu fizyolojik bariyerin sebep olduğu engeli ortadan kaldırmak, ancak geliştirilen yeni stratejilerle mümkün olmaktadır. Nano boyutlu kolloidal sistemler, santral sinir sistemi hastalıklarının tedavisinde pasif ve aktif hedeflendirme yoluyla umut vaat eden yaklaşımlar olarak yer almaktadır. Bu yaklaşımlar arasında reseptör aracılı taşıyıcı RAT sistemler dikkat çekmektedir. Reseptörlere hedeflendirilmek üzere geliştirilen Truva Atı / Molecular Trojan Horse MTH teknolojisi sayesinde büyük moleküllü ilaçların beyine taşınmasına olanak sağlanmıştır. Hedeflendirilmiş taşıyıcı sistemlerin SSS’de kullanımları ile ilgili araştırmalar, günümüzde beyin kanseri, inme, Alzheimer, Parkinson, beyin travması gibi hastalıklar üzerinde yoğunlaşmaktadır. Bu çalışmanın amacı, kolloidal sistemlerin hedeflendirilmesinde kullanılan yaklaşımların ve güncel çalışmaların değerlendirilmesi ile yeni stratejilerin belirlenmesine olanak sağlamaktır.

🔖

Cite This Article

DOĞAN, S. S., TOKTAŞ, S., ÇAPAN, Y. (2014). Beyine İlaç Tașınması: Truva Atı Teknolojisi. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Sayı: 1, 1–16. https://ajindex.com/articles/762356

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Beduneau, A., Saulnier, P.,Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 28 (33), 4947-4967 (2007).
  2. Garcia-Garcia, E., Andrieux, K., Gil, S.,Couvreur, P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm, 298 (2), 274-292 (2005).
  3. Harikrishna Devalapally, A.C., Mansoor M. Amiji. Role of nanotechnology in pharmaceutical product development. Journal of Pharmaceutical Sciences, 96 (10), 2547-2565 (2007).
  4. Schnyder, A.,Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx, 2 (1), 99-107 (2005).
  5. VJ Mohanraj, Y.C. Nanoparticles – A Review. Tropical Journal of Pharmaceutical Research, 5 (1), 561-573 (2006).
  6. Newton, H.B. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother, 6 (10), 1495-1509 (2006).
  7. K. Ringe, C.M.W., B. A. Sabe. Nanoparticle Drug Delivery to the Brain. Encyclopedia of Nanoscience and Nanotechnology, 7, 91-104 (2004).
  8. Mittal, G., Carswell, H., Brett, R., Currie, S.,Kumar, M.N. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer’s pathology. J Control Release (2010).
  9. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47 (1), 65-81 (2001).
  10. Pardridge, W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol, 6 (5), 494-500 (2006).
  11. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics, 2 (1), 3-14 (2005).
  12. Pardridge, W.M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem, 19 (7), 1327-1338 (2008).
  13. Pardridge, W.M. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol, 59 (1), 35-40 (2002).
  14. Hwa Jeong Lee, B.E., Jayne Lesley, Ulrich Bickel, William M. Pardridge. Targeting Rat Anti- Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse. The journal of pharmacology and experimental therapeutics, 292 (3), 1048-1052 (2000).
  15. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov Today, 12 (1-2), 54-61 (2007).
  16. Bickel, U., Yoshikawa, T.,Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev, 46 (1-3), 247-279 (2001).
  17. Yesim Aktas, M.Y., Karine Andrieux, R. Neslihan Gursoy, Maria Jose Alonso,, Eduardo Fernandez-Megia, R.N.-C., Emilio Qu